Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.82 |
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.82 |
| ▸ | AKT2 | P31751 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14782571 | 0.90 | AKT1 (1.00) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL16987124 | 0.89 | RPS6KB1 (0.84) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL14782567 | 0.89 | RPS6KB1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL16987146 | 0.89 | AKT1 (0.83) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL16057491 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL18309414 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL16057123 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL16057490 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1AKT2KCNH2AKT3 | |
| SCHEMBL14782390 | 0.89 | AKT1 (1.00) | AKT1RPS6KB1 | |
| SCHEMBL16987133 | 0.88 | RPS6KB1 (0.97) | AKT1RPS6KB1AKT2KCNH2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434714-B2 | Pyrimidine imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | claimed |
| EP-3105224-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-9434714-B2 | Pyrimidine imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434714-B2 | Pyrimidine imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434714-B2 | Pyrimidine imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| WO-2015123174-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123174-A1 | PYRIMIDINE IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225371-A1 | Novel Pyrimidine Imidazole Amines as Modulators of Kinase Activity | TK1, CHEK2, DCK | AKT1 397/4885RPS6KB1 336/4885AKT2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.